Nephrology

The results of a new survey regarding quality of care for end stage renal disease patients raise questions about how to improve the quality of end-of-life care.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

In an extensive review of 18 cohort studies, investigators connect dietary patterns with chronic kidney disease incidence rates.

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

The CREDENCE study of canagliflozin in adults with chronic kidney disease and type 2 diabetes met its primary endpoint as well as cardiovascular endpoints.

The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Positive data collected from 2 phase 2 trials evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) have been reported.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Dimerix shares update on DMX-200, a combination therapy of propagermanium and irbesartan for the treatment of focal segmental sclerosis in addition to chronic kidney disease.

Despite a considerable gap between the number of patients who require a transplant and the number of organs available those patients fortunate enough to receive the lifesaving organs are seeing greater success from the procedure.

There is no shortage of people in need of a kidney transplant but a considerable shortage in the number of organs available to these patients. Despite that health care professionals in nephrology are determined to provide their patients the highest quality of life possible in spite of these challenges.

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.

Mortality in patients with type 1 diabetes mellitus (T1DM) is higher than in the general population, and whether mortality improves or alters with glycemic control is unknown.

Lack of sleep and chronic kidney disease (CKD) independently lead to hypertension, diabetes mellitus, lower quality of life, and shorter life expectancy. Severity of CKD and sleep disturbances may also worsen diabetes and hypertension synergistically.

The US Food and Drug Administration (FDA) issued a strong warning on a drug used to treat iron deficiency anemia in patients with chronic kidney disease. Intravenous injections of ferumoxytol (Feraheme/Amag Pharmaceuticals) can cause serious allergic reactions including death in patients who are sensitive to the drug, the FDA cautioned in a new boxed warning. The drug was approved in 2009.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reported that one in 10 American adults had some level of chronic kidney disease (CKD), and that kidney disease is the 9th leading cause of death in the US.

Kidney donors may have lower 1,25-dihydroxyvitamin D and phosphate levels. Their parathyroid hormone levels may be elevated, but with minimal effect on calcium levels.

Despite these improvements in medical technology, diabetic nephropathy remains unpredictable and life-threatening. Identifying high-risk patients at an early stage could help clinicians take appropriate steps to reduce risk.

Patients who have chronic kidney disease (CKD) and end-stage renal disease (ESRD) require 20% less warfarin and more monitoring for bleeding than patients who have normal kidney function.

Results from the TEMPO trial presented at Kidney Week 2012 show that treatment with tolvaptan slowed the increase in total kidney volume and the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).